Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATN-224 in Biochemically Relapsed Prostate Cancer
NCT00405574Phase 2Unknown
- Sponsor
- Attenuon LLC
- Start
- Nov 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atn-224 in prostate cancer (PCa) (2 arms), sponsored by Attenuon LLC. Primary endpoint: Proportion of patients who do not have PSA progression at 24 weeks. Status: unknown.
02
Drugs
atn-224
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00405574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405574.